학술논문

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
Document Type
article
Source
Alzheimer's & dementia : the journal of the Alzheimer's Association. 16(1)
Subject
Humans
Atrophy
Magnetic Resonance Imaging
Clinical Trials as Topic
Congresses as Topic
Frontotemporal Lobar Degeneration
Biomarkers
ARTFL
Biomarker
C9orf72
Clinical trial
FTD
FTLD
Frontotemporal dementia
Frontotemporal lobar degeneration
GRN
LEFFTDS
MAPT
Primary progressive aphasia
Progressive supranuclear palsy
Brain Disorders
Genetics
Acquired Cognitive Impairment
Dementia
Clinical Trials and Supportive Activities
Alzheimer's Disease Related Dementias (ADRD)
Frontotemporal Dementia (FTD)
Rare Diseases
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Clinical Research
Neurodegenerative
Geriatrics
Clinical Sciences
Neurosciences
Language
Abstract
IntroductionFrontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years of age. Increasing numbers of therapeutics targeting FTLD syndromes are being developed.MethodsIn March 2018, the Association for Frontotemporal Degeneration convened the Frontotemporal Degeneration Study Group meeting in Washington, DC, to discuss advances in the clinical science of FTLD.ResultsChallenges exist for conducting clinical trials in FTLD. Two of the greatest challenges are (1) the heterogeneity of FTLD syndromes leading to difficulties in efficiently measuring treatment effects and (2) the rarity of FTLD disorders leading to recruitment challenges.DiscussionNew personalized endpoints that are clinically meaningful to individuals and their families should be developed. Personalized approaches to analyzing MRI data, development of new fluid biomarkers and wearable technologies will help to improve the power to detect treatment effects in FTLD clinical trials and enable new, clinical trial designs, possibly leveraged from the experience of oncology trials. A computational visualization and analysis platform that can support novel analyses of combined clinical, genetic, imaging, biomarker data with other novel modalities will be critical to the success of these endeavors.